Download Free Drugs And The Cell Cycle Book in PDF and EPUB Free Download. You can read online Drugs And The Cell Cycle and write the review.

Drugs and the Cell Cycle provides an introduction to fundamental principles and studies on the mechanisms of drug action on proliferating cells. The book is intended to reduce the time lag between observation and practical application. Comprised of 10 chapters, the book describes the plant alkaloids, alkylating agents, mercurials, adrenergic agents, radiomimetics, narcotics, hallucinogens, mitogens, hepatotoxins, antiobiotics, and antimetabolites of various types. The text also emphasizes the drugs used in cancer chemotherapy, and the in vitro and in vivo cell systems of bacteria, protozoa, sea urchins, and mammals. The concepts are presented with comprehensive illustrations and tables to help readers obtain more efficient understanding and learning. The information and concepts presented in this volume will be of great interest to scientists and students in many disciplines, including physiology, pharmacology, and oncology, as well as cellular, molecular, and developmental biology. The book will also fill the gap between drug experimental observations and their potential relevance to man.
This treatise had its origins in the authors' strong opinion that the discovery of new drugs, especially of innovative therapeutic agents, really does not happen as a spontaneous sequel to investiga tive research, no matter how penetrating such research may be. Rather, it seemed to us that the discovery of innovative therapeutic agents was a very active process, existing in and of itself, and demanding full attention-it was not simply a passive, dependent by-process of investigative research. And yet, many researchers some close confreres of the authors, others more distant-believed otherwise. We felt that their view reflected unrealistic thinking and that reality probably lay closer to what Beyer" maintained: We are taught to believe that if we can understand a disease it should be easy enough to figure out, say, the molecular configuration of a definitive receptor mechanism somewhere along the line and to design a specific drug . . . . And so we start out to understand the disease but never get around to doing much about therapy. The authors very soon realized that there was essentially no quantitive information available on just where and how innovative therapeutic agents were discovered. There were only anecdotal accounts, and these were able to be selected and presented in ways that could be used to defend any point of view.
This book explains the pharmacological relationships between the various systems in the human body. It offers a comprehensive overview of the pharmacology concerning the autonomic, central, and peripheral nervous systems. Presenting up-to-date information on chemical mediators and their significance, it highlights the therapeutic aspects of several diseases affecting the cardiovascular, renal, respiratory, gastrointestinal, endocrinal, and hematopoietic systems. The book also includes drug therapy for microbial and neoplastic diseases. It also comprises sections on immunopharmacology, dermatological, and ocular pharmacology providing valuable insights into these emerging and recent topics. Covering the diverse groups of drugs acting on different systems, the book reviews their actions, clinical uses, adverse effects, interactions, and subcellular mechanisms of action. It is divided into 11 parts, subdivided into several chapters that evaluate the basic pharmacological principles that govern the different types of body systems. This book is intended for academicians, researchers, and clinicians in industry and academic institutions in pharmaceutical, pharmacological sciences, pharmacy, medical sciences, physiology, neurosciences, biochemistry, molecular biology and other allied health sciences.
Epigenetics and Dermatology explores the role of epigenetics in the pathogenesis of autoimmune-related skin diseases and skin cancer. Leading contributors cover common and uncommon skin conditions in which extensive epigenetic research has been done. They explain how environmental exposures (chemicals, drugs, sunlight, diet, stress, smoking, infection, etc.) in all stages of life (from a fetus in-utero to an elderly person) may result in epigenetic changes that lead to development of some skin diseases in life. They also discuss the possibilities of new and emergent epigenetic treatments which are gradually being adopted in management of various skin diseases. Chapters follow a conventional structure, covering fundamental biology of the disease condition, etiology and pathogenesis, diagnosis, commonly available treatments, and epigenetic therapy where applicable. Discusses the basic biology of skin diseases and skin cancers induced or aggravated by aberrant epigenetic changes Evaluates how to approach autoimmune-related skin diseases from a therapeutic perspective using the wealth of emergent epigenetic clinical trials Offers a coherent and structured table of contents with basic epigenetic biology followed by discussion of the spectrum of rheumatologic through neoplastic skin diseases, finally ending with a discourse on epigenetic therapy
Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector. The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver). The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. - Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies, including the cancer epigenome atlas - Discusses targeted isoform specific versus pan-specific inhibitors, a rational drug design approach to epigenetics relevant to pharmacoepigenetic clinical applications - Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs
The "Progress in Cell Cycle Research" series is dedicated to serve as a collection of reviews on various aspects of the cell division cycle, with special emphasis on less studied aspects. We hope this series will continue to be helpful to students, graduates and researchers interested in the cell cycle area and related fields. We hope that reading of these chapters will constitute a "point of entry" into specific aspects of this vast and fast moving field of research. As PCCR4 is being printed several other books on the cell cycle have appeared (ref. 1-3) which should complement our series. This fourth volume of PCCR starts with a review on RAS pathways and how they impinge on the cell cycle (chapter 1). In chapter 2, an overview is presented on the links between cell anchorage -cytoskeleton and cell cycle progression. A model of the Gl control in mammalian cells is provided in chapter 3. The role of histone acetylation and cell cycle contriol is described in chapter 4. Then follow a few reviews dedicated to specific cell cycle regulators: the 14-3-3 protein (chapter 5), the cdc7/Dbf4 protein kinase (chapter 6), the two products of the pI6/CDKN2A locus and their link with Rb and p53 (chapter 7), the Ph085 cyclin-dependent kinases in yeast (chapter 9), the cdc25 phophatase (chapter 10), RCCI and ran (chapter 13). The intriguing phosphorylation dependent prolyl-isomerization process and its function in cell cycle regulation are reviewed in chapter 8.
A fundamental and groundbreaking reassessment of how we view and manage cancer When we think of the forces driving cancer, we don’t necessarily think of evolution. But evolution and cancer are closely linked because the historical processes that created life also created cancer. The Cheating Cell delves into this extraordinary relationship, and shows that by understanding cancer’s evolutionary origins, researchers can come up with more effective, revolutionary treatments. Athena Aktipis goes back billions of years to explore when unicellular forms became multicellular organisms. Within these bodies of cooperating cells, cheating ones arose, overusing resources and replicating out of control, giving rise to cancer. Aktipis illustrates how evolution has paved the way for cancer’s ubiquity, and why it will exist as long as multicellular life does. Even so, she argues, this doesn’t mean we should give up on treating cancer—in fact, evolutionary approaches offer new and promising options for the disease’s prevention and treatments that aim at long-term management rather than simple eradication. Looking across species—from sponges and cacti to dogs and elephants—we are discovering new mechanisms of tumor suppression and the many ways that multicellular life-forms have evolved to keep cancer under control. By accepting that cancer is a part of our biological past, present, and future—and that we cannot win a war against evolution—treatments can become smarter, more strategic, and more humane. Unifying the latest research from biology, ecology, medicine, and social science, The Cheating Cell challenges us to rethink cancer’s fundamental nature and our relationship to it.
Leading clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell cycle control and demonstrate its clinical relevance to understanding neoplastic diseases. Topics range from Cdk inhibitors and cell cycle regulators to the prognostic value of p27 and tumor suppressor genes as diagnostic tools. Actual case studies show how the new molecular understanding has produced such drugs as Flavopiridol and Sulindac. The book brings all the recent critical research findings to bear on clinical practice, and clearly shows their powerful impact on the diagnostics, prognostics, and therapeutics of cancer, AIDS, and cardiovascular disease.